Literature DB >> 26897067

Cryptococcosis.

Eileen K Maziarz1, John R Perfect2.   

Abstract

Cryptococcosis is an invasive mycosis caused by pathogenic encapsulated yeasts in the genus Cryptococcus. Cryptococcus gained prominence as a pathogen capable of widespread disease outbreaks in vulnerable populations. We have gained insight into the pathobiology of Cryptococcus, including the yeast' s capacity to adapt to environmental pressures, exploit new geographic environments, and cause disease in both immunocompromised and apparently immunocompetent hosts. Inexpensive, point-of-care testing makes diagnosis more feasible than ever. The associated worldwide burden and mortality remains unacceptably high. Novel screening strategies and preemptive therapy offer promise at making a sustained and much needed impact on this sugar-coated opportunistic mycosis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central nervous system (CNS) infection; Cryptococcosis; HIV/AIDS; Immune reconstitution inflammatory syndrome (IRIS); Opportunistic mycoses; Solid organ transplantation (SOT)

Mesh:

Substances:

Year:  2016        PMID: 26897067      PMCID: PMC5808417          DOI: 10.1016/j.idc.2015.10.006

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  185 in total

1.  Comparison of four assays for the detection of cryptococcal antigen.

Authors:  M J Binnicker; D J Jespersen; J E Bestrom; L O Rollins
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

Review 2.  Cryptococcal osteomyelitis: case report and review.

Authors:  P Y Liu
Journal:  Diagn Microbiol Infect Dis       Date:  1998-01       Impact factor: 2.803

3.  Disseminated cryptococcosis after transurethral resection of the prostate.

Authors:  R Allen; C E Barter; L L Chachoua; L Cleeve; J M O'Connell; F J Daniel
Journal:  Aust N Z J Med       Date:  1982-08

Review 4.  Spread of Cryptococcus gattii into Pacific Northwest region of the United States.

Authors:  Kausik Datta; Karen H Bartlett; Rebecca Baer; Edmond Byrnes; Eleni Galanis; Joseph Heitman; Linda Hoang; Mira J Leslie; Laura MacDougall; Shelley S Magill; Muhammad G Morshed; Kieren A Marr
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

5.  Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression.

Authors:  Hsin-Yun Sun; Barbara D Alexander; Shirish Huprikar; Graeme N Forrest; Didier Bruno; G Marshall Lyon; Dannah Wray; Leonard B Johnson; Costi D Sifri; Raymund R Razonable; Michele I Morris; Valentina Stosor; Marilyn M Wagener; Nina Singh
Journal:  Clin Infect Dis       Date:  2014-09-09       Impact factor: 9.079

6.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

7.  Control of Cryptococcus neoformans in nature by biotic factors.

Authors:  A Ruiz; J B Neilson; G S Bulmer
Journal:  Sabouraudia       Date:  1982-03

8.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

9.  A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis.

Authors:  Arthur T Jackson; Jesse C Nussbaum; Jacob Phulusa; Dan Namarika; Maria Chikasema; Creto Kanyemba; Joseph N Jarvis; Shabbar Jaffar; Mina C Hosseinipour; Charles van der Horst; Thomas S Harrison
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

10.  Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis.

Authors:  Mark D Lindsley; Nanthawan Mekha; Henry C Baggett; Yupha Surinthong; Rinrapas Autthateinchai; Pongpun Sawatwong; Julie R Harris; Benjamin J Park; Tom Chiller; S Arunmozhi Balajee; Natteewan Poonwan
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

View more
  144 in total

1.  Contribution of Laccase Expression to Immune Response against Cryptococcus gattii Infection.

Authors:  Adithap Hansakon; Popchai Ngamskulrungroj; Pornpimon Angkasekwinai
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Impact of Infectious Diseases Consultation on Mortality of Cryptococcal infection in Patients without HIV.

Authors:  Andrej Spec; Margaret A Olsen; Krunal Raval; William G Powderly
Journal:  Clin Infect Dis       Date:  2016-12-07       Impact factor: 9.079

Review 4.  Combinatorial strategies for combating invasive fungal infections.

Authors:  Michaela Spitzer; Nicole Robbins; Gerard D Wright
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

5.  Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans.

Authors:  Fatima Zohra Delma; Abdullah M S Al-Hatmi; Jochem B Buil; Hein van der Lee; Marlou Tehupeiory-Kooreman; G Sybren de Hoog; Joseph Meletiadis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Disseminated Cryptococcosis in a Young Immunocompetent Male.

Authors:  Saurabh Donald; Naveen Kakkar; Vikas Loomba
Journal:  Indian J Hematol Blood Transfus       Date:  2020-03-03       Impact factor: 0.900

7.  Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience.

Authors:  Hiram Villanueva-Lozano; Rogelio de J Treviño-Rangel; Gloria M González; Pedro A Hernández-Rodríguez; Adrián Camacho-Ortiz; Luis Castillo-Reyna; Sandra G Galindo-Alvarado; Michel F Martínez-Reséndez
Journal:  Infection       Date:  2017-08-16       Impact factor: 3.553

8.  Fungal Microbiomes Associated with Green and Non-Green Building Materials.

Authors:  Kanistha Coombs; Stephen Vesper; Brett J Green; Mikhail Yermakov; Tiina Reponen
Journal:  Int Biodeterior Biodegradation       Date:  2017       Impact factor: 4.320

9.  Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study.

Authors:  I N Hakyemez; H Erdem; G Beraud; M Lurdes; A Silva-Pinto; C Alexandru; B Bishop; F Mangani; X Argemi; M Poinot; R Hasbun; M Sunbul; M Akcaer; S Alp; T Demirdal; K Angamuthu; F Amer; E Ragab; G A Shehata; D Ozturk-Engin; N Ozgunes; L Larsen; S Zimmerli; O R Sipahi; E Tukenmez Tigen; G Celebi; N Oztoprak; A C Yardimci; Y Cag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-08       Impact factor: 3.267

10.  Use of Fungal Diagnostics and Therapy in Pediatric Cancer Patients in Resource-Limited Settings.

Authors:  Sheena Mukkada; Jeannette Kirby; Nopporn Apiwattanakul; Randall T Hayden; Miguela A Caniza
Journal:  Curr Clin Microbiol Rep       Date:  2016-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.